Five accelerated schedules for the tick-borne encephalitis vaccine FSME-Immun® in last-minute travellers: an open-label, single-centre, randomized controlled pilot trial

Author:

Berens-Riha Nicole12,Andries Petra3,Aerssens Annelies4,Ledure Quentin5,Van Der Beken Yolien6,Heyndrickx Leo7,Genbrugge Els8,Tsoumanis Achilleas8,Van Herrewege Yven8,Ariën Kevin K27,Van Innis Martine5,Vanbrabant Peter3,Soentjens Patrick13,Spiessens An,Landuyt Hanne,de Viron Emeline,Zaman Kristy,Dooms Eric,Djebara Sarah,Ghoos Katrijn,Michiels Johan,Willems Betty,Buyze Jozefien,Damanet Benjamin,De Koninck Katrien,Hing Mony,De Hondt Annelies,

Affiliation:

1. Institute of Tropical Medicine Department of Clinical Sciences, , Antwerp, Belgium

2. University of Antwerp Department of Biomedical Sciences, , Antwerp, Belgium

3. Centre for Infectious Diseases, Queen Astrid Military Hospital , Brussels, Belgium

4. Ghent University Hospital Department of Internal Medicine and Infectious Diseases, , Belgium

5. Hospital Pharmacy, Queen Astrid Military Hospital , Brussels, Belgium

6. Clinical Laboratory, Queen Astrid Military Hospital , Brussels, Belgium

7. Institute of Tropical Medicine Virology Unit, , Antwerp, Belgium

8. Institute of Tropical Medicine Clinical Trials Unit, , Antwerp, Belgium

Abstract

Abstract Background The purpose of this exploratory study was to evaluate different accelerated tick-borne encephalitis (TBE) vaccine schedules for last-minute travellers. Methods In a single-centre, open-label pilot study, 77 TBE-naïve Belgian soldiers were randomized to one of the following five schedules with FSME-Immun®: group 1 (‘classical accelerated’ schedule) received one intramuscular (IM) dose at Day 0 and Day 14, group 2 two IM doses at Day 0, group 3 two intradermal (ID) doses at Day 0, group 4 two ID doses at Day 0 and Day 7 and group 5 two ID doses at Day 0 and Day 14. The last dose(s) of the primary vaccination scheme were given after 1 year: IM (1 dose) or ID (2 doses). TBE virus neutralizing antibodies were measured in a plaque reduction neutralization test (PRNT90 and 50) at Days 0, 14, 21, 28, Months 3, 6, 12 and 12+21 days. Seropositivity was defined as neutralizing antibody titres ≥10. Results The median age was 19–19.5 years in each group. Median time to seropositivity up to Day 28 was shortest for PRNT90 in ID-group 4 and for PRNT50 in all ID groups. Seroconversion until Day 28 peaked highest for PRNT90 in ID-group 4 (79%) and for PRNT50 in ID-groups 4 and 5 (both 100%). Seropositivity after the last vaccination after 12 months was high in all groups. Previous yellow fever vaccination was reported in 16% and associated with lower geometric mean titres of TBE-specific antibodies at all-time points. The vaccine was generally well tolerated. However, mild to moderate local reactions occurred in 73–100% of ID compared with 0–38% of IM vaccinations, and persistent discolouration was observed in nine ID vaccinated individuals. Conclusion The accelerated two-visit ID schedules might offer a better immunological alternative to the recommended classical accelerated IM schedule, but an aluminium-free vaccine would be preferable.

Funder

Institute of Tropical Medicine of Antwerp

Royal Higher Institute for Defense Brussels

Publisher

Oxford University Press (OUP)

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3